News

Started in late July 2014, the Phase IIa trial is being conducted under an investigational new drug (IND) application filed by the company’s licensor, the Blanchette Rockefeller Neuroscience

As part of the deal, the two parties will jointly work on projects, based on an overarching research plan, in the HBV and liver cancer fields with funding

Produced using proprietary technology, Nagase’s unnatural amino acids are unique chiral building blocks for small molecule and peptide synthesis and can help overcome challenges in designing next-generation drug

Published in the November edition of the Drug Information Association’s Therapeutic Innovation & Regulatory Science (TIRS) journal, the results of the analysis support the TransCelerate-proposed methodology for risk-based

Biologic medicines are produced in living cells and the new Tuas facility encompasses multiple technologies to enable greater speed, productivity and flexibility in commercial-scale manufacturing. Built in less

APL-130277 is the Company’s fast-acting, sublingual, thin filmstrip formulation of apomorphine. OFF episodes are a complication of Parkinson’s disease that leave patients rigid and unable to move and

Both the diabetes and CV standards were established in an effort to make clinical research more efficient while continuing to support the scientific nature of the research. The

Recently, the company has also started a multi-centre Phase Ib trial of BGB324, a selective inhibitor of Axl, in AML patients. The two-part trial is primarily designed to

The Omega-3 fish oil will be sold under the name ‘TapouT’ with all revenues flowing directly into Axxess Pharma. Omega-3 fatty acids are some of the most important